LeePeterHartnerMD

Oncology • Philadelphia, PA

Gastrointestinal Cancer, Head & Neck Cancer, Hematologic Oncology, Sarcoma

Assistant Clinical Professor of Medicine, University Pennsylvania

Join to view full profile

Dr. Hartner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hartner's full profile

Already have an account?

Office
230 W Washington Sq
2nd Floor
Philadelphia, PA 19106
Phone+1 215-829-6088

Fax+1 215-829-6104

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1994 - 1997
Tufts University School of MedicineClass of 1994

Certifications & Licensure

PA State Medical License 2004 - 2026
MA State Medical License 2001 - 2006
CT State Medical License 2000 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01
Completed
Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma Start of enrollment: 2011 Apr 01
Completed
Phase 2
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung Start of enrollment: 2013 Apr 01
Terminated
Phase 2
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
COMPLETED
PHASE3
Join now to see all

Publications & Presentations

PubMed

2 citations
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC...
Yvonne M Mowery, Karla V Ballman, Angela M Hong, Scott M Schuetze, Andrew J Wagner
Lancet. 2024-11-23
2 citations
Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.
Elizabeth T Loggers, Rashmi Chugh, Noah Federman, Lee Hartner, Richard F Riedel
Cancer. 2024-08-15
67 citations
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
Mrinal Gounder, Ravin Ratan, Thierry Alcindor, Patrick Schöffski, Winette T van der Graaf
The New England Journal of Medicine. 2023-03-09

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
Connective Tissue Oncology Society
Member